Progyny Inc (PGNY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Progyny Inc stock (PGNY) is currently trading at $17.75. Progyny Inc PE ratio is 27.77. Progyny Inc PS ratio (Price-to-Sales) is 1.15. Analyst consensus price target for PGNY is $27.45. WallStSmart rates PGNY as Underperform.
- PGNY PE ratio analysis and historical PE chart
- PGNY PS ratio (Price-to-Sales) history and trend
- PGNY intrinsic value — DCF, Graham Number, EPV models
- PGNY stock price prediction 2025 2026 2027 2028 2029 2030
- PGNY fair value vs current price
- PGNY insider transactions and insider buying
- Is PGNY undervalued or overvalued?
- Progyny Inc financial analysis — revenue, earnings, cash flow
- PGNY Piotroski F-Score and Altman Z-Score
- PGNY analyst price target and Smart Rating
Progyny Inc
📊 No data available
Try selecting a different time range
PGNY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Progyny Inc (PGNY)
PGNY appears undervalued based on the Graham Formula, trading 17% below its estimated fair value of $25.84.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Progyny Inc (PGNY) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, eps growth, institutional own.. Concerns around operating margin and profit margin. Mixed signals suggest waiting for clearer direction before acting.
Progyny Inc (PGNY) Key Strengths (3)
107.58% of shares held by major funds and institutions
Paying $1.15 for every $1 of annual revenue
Strong earnings growth at 20.60% per year
Supporting Valuation Data
Progyny Inc (PGNY) Areas to Watch (6)
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Modest revenue growth at 6.70%
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Fairly priced relative to book value
Supporting Valuation Data
Progyny Inc (PGNY) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, EPS Growth. Valuation metrics including Price/Sales (1.15) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 20.60%.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Revenue Growth. Some valuation metrics including Price/Book (2.88) suggest expensive pricing. Growth concerns include Revenue Growth at 6.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.50%, Operating Margin at 7.20%, Profit Margin at 4.54%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Price/Sales) and negatives (Operating Margin, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PGNY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PGNY's Price-to-Sales ratio of 1.15x sits near its historical average of 1.15x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 3% below its historical high of 1.18x set in Mar 2026, and 3% above its historical low of 1.11x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Progyny Inc (PGNY) · HEALTHCARE › HEALTHCARE PLANS
The Big Picture
Progyny Inc is a mature, profitable business with steady cash generation. Revenue reached 1.3B with 7% growth year-over-year. Profit margins are strong at 454.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 1250.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 49M in free cash flow and 54M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor HEALTHCARE PLANS industry trends, competitive moves, and regulatory changes that could impact Progyny Inc.
Bottom Line
Progyny Inc is a well-established business delivering consistent profitability with 454.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Progyny Inc(PGNY)
NASDAQ
HEALTHCARE
HEALTHCARE PLANS
USA
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.